Lin Richard J, Ma Helen, Guo Robin, Troxel Andrea B, Diefenbach Catherine S
Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Division of Hematology and Medical Oncology, Laura & Isaac Perlmutter Cancer Center at New York University Langone Medical Center, New York, NY, USA.
Br J Haematol. 2018 Jan;180(2):267-270. doi: 10.1111/bjh.15027. Epub 2017 Nov 16.
Survival outcomes for elderly lymphoma patients are disproportionally inferior to those of younger patients. We examined medication usage at diagnosis for 171 elderly patients (median age 70 years) with aggressive non-Hodgkin lymphoma treated between 2009 and 2014. At least one potentially inappropriate medication was used in 47% of patients according to the Beers Criteria, 59% experienced treatment delays and/or dose reduction and 65% experienced ≥ grade 3 treatment-related toxicities. We report here for the first time that potentially inappropriate medication use was associated with reduced progression-free survival and overall survival, and increased ≥ grade 3 treatment-related toxicities in multivariate analysis.
老年淋巴瘤患者的生存结果相较于年轻患者要差得多。我们研究了2009年至2014年间接受治疗的171例老年（中位年龄70岁）侵袭性非霍奇金淋巴瘤患者在诊断时的用药情况。根据Beers标准，47%的患者至少使用了一种潜在不适当药物，59%的患者经历了治疗延迟和/或剂量减少，65%的患者经历了≥3级治疗相关毒性。我们首次在此报告，在多变量分析中，潜在不适当药物的使用与无进展生存期和总生存期缩短以及≥3级治疗相关毒性增加有关。
